The Latest Breaking News from AbbVie

With a strong product portfolio, this growth and income stock is an excellent long-term investment.

Although Abbvie stock has been lagging behind the broader market over the past year, Wall Street analysts are still moderately bullish about its outlook.

This article covers three buy-rated companies that've increased their dividends for 50+ consecutive years.

Amid healthcare’s enduring importance and increasing demand for its products and services, here are five dividend-paying healthcare stocks to consider now.

AbbVie is "firing on all cylinders," an analyst said Friday after the firm beat first-quarter estimates. But AbbVie stock fell.

June S&P 500 E-Mini futures (ESM24) are up +0.63%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.86% this morning as upbeat quarterly results from tech titans Alphabet and Microsoft boosted sentiment, while investors geared up for the release of the Fed’s preferred inflation gauge.

The pharmaceutical industry is expected to expand significantly due to the ever-rising global medical needs and technological advances. In this scenario, let’s analyze the better investment option between popular pharma stocks, Merck &Co (MRK) and AbbVie (ABBV).

The CDC warned doctors about "counterfeit or mishandled" Botox injections that have caused clusters of illness in the U.S.

AbbVie stock has slumped 9% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.

Public health authorities are investigating reports of counterfeit injections sickening 19 people across nine states. Experts say getting bona fide Botox starts with finding a trustworthy provider.

Officials said that all the incidents involved women who reported sick following the administration of counterfeit Botox injections of AbbVie or those who received injections from unlicensed or untrained individuals in non-healthcare environments.